Prostacyclin: A Potent Antimetastatic Agent
- 12 June 1981
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 212 (4500), 1270-1272
- https://doi.org/10.1126/science.7015512
Abstract
Metastasis is the principal cause of failures to cure human cancers. Prostacyclin is a powerful antimetastatic agent against B16 amelanotic melanoma cells. This effect, which may result from the platelet antiaggregatory action of prostacyclin, is potentiated by a phosphodiesterase inhibitor. Inhibitors of prostacyclin synthesis increase metastasis. Prostacyclin and agents that may increase endogenous prostacyclin production or prolong its activity are suggested as new antimetastatic agents.Keywords
This publication has 16 references indexed in Scilit:
- Lysosomal Cathepsin B: Correlation with Metastatic PotentialScience, 1981
- Albumins stabilize prostaglandin I2Prostaglandins, 1980
- The pathogenesis of cancer metastasisNature, 1980
- Prostacyclin inhibits mobilisation of fibrinogen-binding sites on human ADP- and thrombin-treated plateletsNature, 1980
- Prostaglandin D2 controls pulmonary metastasis of malignant melanoma cellsNature, 1979
- Pulmonary vasodilator activity of prostacyclin (PGI2) in the cat.Circulation Research, 1979
- Inhibition of DNA synthesis in harding-passey melanoma cells by prostaglandins A1 and A2: Comparison with chemotherapeutic agentsBiochemical and Biophysical Research Communications, 1979
- Prostacyclin is a circulating hormoneNature, 1978
- Further studies on the enzymatic conversion of prostaglandin endoperoxide into prostacyclin by porcine aorta microsomesBiochimica et Biophysica Acta (BBA) - Enzymology, 1978
- Platelet—tumor‐cell interactions in mice. The role of platelets in the spread of malignant diseaseInternational Journal of Cancer, 1973